查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466242

皮質類固醇抑制劑市場：按藥物、治療類型、分銷管道和最終用戶分類 - 全球預測 2024-2030

Adrenal Corticosteroid Inhibitors Market by Drug (Aminoglutethimide, Levoketoconazole, Metyrapone), Treatment Type (Breast Cancer, Cushing's Syndrome, Prostate Cancer), Distribution Channel, End-user - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年皮質類固醇抑制劑市場規模為24.9億美元，預計2024年將達28億美元，2030年將達57.8億美元，複合年成長率為12.75%。

皮質類固醇抑制劑是一組藥物化合物，旨在抑制體內皮質醇和其他腎上腺皮質荷爾蒙的產生和抑製作用。腎上腺皮質荷爾蒙是一組主要由位於腎臟上方的腎上腺所產生的荷爾蒙。這些荷爾蒙調節許多生理過程，包括免疫反應、發炎、壓力、新陳代謝和血壓。肥胖、第2型糖尿病和卵巢症候群等內分泌疾病的流行導致對基於腎上腺皮質荷爾蒙抑制劑的治療的需求不斷成長。然而，醫藥品認證過程中的監管障礙可能會對尋求核准新藥或擴大適應症的製藥公司造成嚴重的時間延誤和財務成本。此外，隨著療效、特異性和副作用改善的新藥的持續開發，預計將加速全球最終用途部門對皮質類固醇抑制劑的使用。

主要市場統計
基準年[2023] 24.9億美元
預測年份 [2024] 28億美元
預測年份 [2030] 57.8億美元
複合年成長率（%） 12.75%

奧西洛司他藥物製劑的使用正在迅速增加。

胺基是一種老一代腎上腺類固醇抑制劑，可阻止腎上腺皮質中膽固醇轉化為孕烯醇酮並抑制皮質醇的產生。Ketoconazole是一種新型臨床實驗藥物，透過抑制多種參與類固醇生成的酵素來抑制皮質醇合成，可有效治療內源性庫欣氏症候群。 Metyrapone 是一種皮質類固醇抑制劑，可抑制 11B-氧化酵素（產生皮質醇的酵素）。該藥物用作庫欣氏症候群急性發作患者的短期治療選擇，或用作確定皮質醇反應性的診斷工具。 Osilodrostat 是一種有效的口服 11B-羥化酶抑制劑，已被證明可以快速、持續地降低庫欣氏症患者的平均尿液遊離皮質醇。

治療類型 增加皮質類固醇抑制劑在庫欣氏症候群治療的使用

皮質類固醇抑制劑用於治療荷爾蒙受體陽性（HR+）轉移性乳癌。當Aromatase抑制劑（HR+乳癌的第一線藥物）產生抗藥性時，就會需要這些抑制劑。皮質類固醇抑制劑在庫欣氏症候群的治療中發揮重要作用，庫欣氏症候群是一種由長期暴露於高濃度皮質醇所引起的荷爾蒙失調。這些抑制劑旨在抑制皮質醇的產生並緩解與皮質醇過多相關的症狀，例如肥胖、疲勞和高血壓。儘管進行了初始荷爾蒙療法，但晚期前列腺癌常常由於雄性激素的持續產生而進展。皮質類固醇抑制劑，例如醋酸Abiraterone，與皮質類固醇藥物潑尼鬆一起使用，以抑制雄激素的產生和癌症的生長。

銷售管道：不斷發展的皮質類固醇抑制劑線上分銷管道

醫院藥局為醫院和診所收治的患者提供服務，在皮質類固醇抑制劑的分銷中發揮重要作用。這些設施通常設有現場藥房，以確保藥物（包括皮質類固醇抑制劑）的可及性和可用性。醫院藥局主要直接向製造商和供應商購買藥品。近年來，由於人們對宅配服務的日益偏好以及網際網路在全球範圍內的普及，在線藥房迅速普及。網上藥局提供送貨上門的便利，同時透過直接從製造商和授權經銷商處採購來維持品質保證。但是，請警惕一些不受監管的電子商務網站上銷售的假藥。零售藥局仍然是皮質類固醇抑制劑分銷管道的重要組成部分，因為它們廣泛存在於世界各地的住宅。零售藥局可以快速為需要非成藥藥和處方箋藥的顧客提供服務。

最終用戶：專門中心大量採用皮質類固醇抑制劑

使用皮質類固醇抑制劑的主要場所是醫院，在那裡可以提供需要緊急干預的先進診斷工具和綜合治療。患有嚴重或危及生命的疾病（例如腎上腺腺癌或需要手術的患者）的患者通常在醫院接受抑制劑治療。專科中心專注於為患有特定疾病的患者提供專門護理。當涉及皮質類固醇抑制劑時，這些中心治療罕見內分泌疾病的患者，專業知識和經驗對於處理這些複雜的病例至關重要。

區域洞察

在美洲，我們看到人們對愛迪生氏症、庫欣氏症候群和其他腎上腺皮質疾病的認知不斷提高，大型製藥企業的研究經費不斷增加，大型製藥企業在歐盟國家，由於人們對腎上腺疾病的早期檢測和有效治療方法的認知不斷提高，對皮質類固醇抑制劑的需求正在增加。隨著政府投資改善醫療基礎設施、提高公眾健康意識和促進臨床研究活動，歐洲、中東和非洲地區為腎上腺皮質荷爾蒙抑制劑製造商提供了巨大的機會。隨著製藥公司透過強力的研發策略開發新型抑制劑以及政府政策鼓勵對生物製藥製造廠的投資，皮質類固醇抑制劑在亞太地區不斷成長。此外，線上藥局和分銷平台的出現預計將擴大分銷並改善腎上腺皮質疾病的治療效果。

FPNV定位矩陣

FPNV定位矩陣對於評估皮質類固醇抑制劑市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對皮質類固醇抑制劑市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.皮質類固醇抑制劑市場規模及預測是多少？

2.在皮質類固醇抑制劑市場的預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.皮質類固醇抑制劑市場的技術趨勢和法規結構是什麼？

4.皮質類固醇抑制劑市場主要供應商的市場佔有率為何？

5. 進入皮質類固醇抑制劑市場合適的型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 治療內分泌疾病對皮質類固醇抑制劑的需求不斷增加
      • 政府對基於皮質類固醇抑制劑的藥物的核准增加
    • 抑制因素
      • 與皮質類固醇抑制劑相關的認知度低且成本高
    • 機會
      • 大量投資皮質類固醇抑制劑的研發
      • 先進醫療設施的增加和製藥業的進步
    • 任務
      • 對基於皮質類固醇抑制劑的藥物副作用的擔憂
  • 市場區隔分析
    • 藥物：奧西洛司他藥物的使用激增作為疾病的長期治療選擇
    • 治療類型：增加皮質類固醇抑制劑的使用來治療庫欣氏症候群
    • 交付管道：不斷發展的皮質類固醇抑制劑線上交付管道
    • 最終用戶：專門中心大量採用皮質類固醇抑制劑
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章皮質類固醇抑制劑市場（依藥物）

  • 胺基
  • Ketoconazole
  • 美提拉蓬
  • 振盪器

第7章依治療類型分類的皮質類固醇抑制劑市場

  • 乳癌
  • 庫欣氏症候群
  • 攝護腺癌

第8章皮質類固醇抑制劑市場：按分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章皮質類固醇抑制劑市場：依最終用戶分類

  • 醫院
  • 專業中心

第10章美洲皮質類固醇抑制劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區皮質類固醇抑制劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的皮質類固醇抑制劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Coherus 和君實生物科技宣布 FDA核准LOQTORZI（特瑞普利單抗-tpzi）用於所有復發性或轉移性鼻咽癌 (NPC) 治療線
    • 美國FDA核准雙效錠劑AKEEGA（尼拉帕尼和Abiraterone阿比特龍）用於治療 BRCA 陽性轉移性去勢抗性前列腺癌患者
    • Moderna 和默克公司宣布，臨床實驗性個人化 mRNA 癌症疫苗 mRNA-4157/V940 與 KEYTRUDA®（ Pembrolizumab ）聯合使用在 2b 期 KEYNOTE-942 研究中達到了主要療效終點
  • 戰略分析和建議

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-FB6C9E792FB6

[184 Pages Report] The Adrenal Corticosteroid Inhibitors Market size was estimated at USD 2.49 billion in 2023 and expected to reach USD 2.80 billion in 2024, at a CAGR 12.75% to reach USD 5.78 billion by 2030.

Adrenal corticosteroid inhibitors are a class of pharmaceutical compounds designed to suppress the production or inhibitory action of cortisol and other corticosteroids within the body. Corticosteroids are a group of hormones that are primarily produced by the adrenal glands that are located above each kidney. These hormones regulate numerous physiological processes such as immune response, inflammation, stress, metabolism, and blood pressure. Prevalence of endocrine diseases, including obesity, type 2 diabetes mellitus, and polycystic ovary syndrome, have contributed to a higher need for Adrenal corticosteroid inhibitor-based therapies. However, regulatory hurdles pertaining to drug approval processes can impose significant time delays and financial costs on pharmaceutical companies seeking approval for new drugs or expanded indications. Furthermore, the ongoing development of new drugs with improved efficacy, specificity, and reduced side effects is anticipated to accelerate the use of adrenal corticosteroid inhibitors by the end-use sectors globally.

KEY MARKET STATISTICS
Base Year [2023] USD 2.49 billion
Estimated Year [2024] USD 2.80 billion
Forecast Year [2030] USD 5.78 billion
CAGR (%) 12.75%

Drug: Burgeoning utilization of osilodrostat drug owing to its long-term treatment option for diseases

Aminoglutethimide is an older-generation adrenal steroid inhibitor that stops the conversion of cholesterol to pregnenolone in the adrenal cortex, thereby reducing cortisol production. Levoketoconazole is a novel investigational drug and shows results in treating endogenous Cushing's syndrome by inhibiting cortisol synthesis by blocking multiple enzymes involved in steroidogenesis. Metyrapone is an adrenal corticosteroid inhibitor that inhibits 11B-hydroxylase, an enzyme in cortisol production. This drug is used as a short-term treatment option for patients experiencing acute episodes of Cushing's syndrome or as a diagnostic tool to determine cortisol responsiveness. Osilodrostat is a potent oral inhibitor of 11B-hydroxylase that has demonstrated rapid and sustained reductions in mean urinary-free cortisol levels in patients with Cushing's disease.

Treatment Type: Increasing use of adrenal corticosteroid inhibitors for treating cushing's syndrome

Adrenal corticosteroid inhibitors are utilized in the treatment of hormone-receptor-positive (HR+) metastatic breast cancer. The need for these inhibitors arises when patients become resistant to aromatase inhibitors, which are the first line of treatment for HR+ breast cancer. Adrenal corticosteroid inhibitors play a critical role in managing Cushing's syndrome, a hormonal disorder caused by prolonged exposure to high levels of cortisol. These inhibitors aim to reduce cortisol production and alleviate symptoms associated with cortisol excess, such as obesity, fatigue, and hypertension. Advanced prostate cancer often progresses despite initial hormone therapy due to the continued production of androgen hormones. Adrenal corticosteroid inhibitors, such as abiraterone acetate, are combined with prednisone, a corticosteroid drug, to suppress androgen production and limit cancer growth.

Distribution Channel: Evolving online distribution channel for adrenal corticosteroid inhibitors

In the distribution of adrenal corticosteroid inhibitors, hospital pharmacies play a crucial role, as they cater to patients admitted in hospitals and clinics. These medical facilities usually have an in-house pharmacy, ensuring the accessibility and availability of medications, including adrenal corticosteroid inhibitors. Hospital pharmacies mainly procure drugs directly from manufacturers or suppliers. With the growing preference for home delivery services, online pharmacies have rapidly gained popularity in recent years due to increasing internet penetration worldwide. Online pharmacies offer convenience through door-to-door deliveries while maintaining quality assurance by sourcing directly from manufacturers or authorized distributors. However, there is a need to be cautious regarding counterfeit drugs sold on some unregulated e-commerce websites. Retail pharmacies remain an integral part of the distribution channel landscape for adrenal corticosteroid inhibitors due to their widespread presence across residential areas worldwide. They serve walk-in customers who require over-the-counter or prescription-based medications promptly.

End-user: Significant adoption of adrenal corticosteroid inhibitors in specialty centers

Hospitals remain a primary setting for administering adrenal corticosteroid inhibitors owing to their ability to provide comprehensive care with access to advanced diagnostic tools and emergency intervention if required. Patients with severe or life-threatening conditions, such as adrenal carcinoma or those requiring surgery, often receive their inhibitor treatments in a hospital setting. Specialty centers focus on providing specialized care to patients with specific medical conditions. In the context of adrenal corticosteroid inhibitors, these centers cater to patients with rare endocrine disorders where expert knowledge and experience are vital in managing these complex cases.

Regional Insights

The adrenal corticosteroid inhibitors market is evolving in the Americas owing to the growing awareness of Addison's disease, Cushing's syndrome, and other adrenocortical disorders, increased research funding from the and collaboration with major pharmaceutical companies facilitating advanced clinical trials and novel drug development. In EU countries, the demand for adrenal corticosteroid inhibitors has escalated due to increased awareness about early detection and effective treatment options for adrenal diseases. The EMEA region represents a significant opportunity for adrenal corticosteroid inhibitor manufacturers as governments invest in improving healthcare infrastructure, raising public health awareness, and promoting clinical research activities. Adrenal corticosteroid inhibitors are growing in the APAC region, with pharmaceutical companies developing novel inhibitors through robust R&D strategies and government policies encouraging investment in biopharmaceutical manufacturing plants. Furthermore, the emergence of online pharmacy and distribution platforms is anticipated to expand the distribution and improve the treatment outcomes of adrenocortical medical conditions.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Adrenal Corticosteroid Inhibitors Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Adrenal Corticosteroid Inhibitors Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Adrenal Corticosteroid Inhibitors Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adooq Bioscience LLC, Cayman Chemical Company, Crinetics Pharmaceuticals, Inc., Eli Lilly and Company, Enzo Life Sciences, Inc., Hefei Home Sunshine Pharmaceutical Technology Co., Ltd., HRA Pharma Rare Diseases SAS by Perrigo Company plc, MedChemExpress, Merck KGaA, Novartis AG, Orphagen Pharmaceuticals, Pfizer Inc., Sparrow Pharmaceuticals Inc., Steris Healthcare PVT Ltd, Tocris Bioscience by Bio-Techne Corporation, and Xeris Biopharma Holdings, Inc..

Market Segmentation & Coverage

This research report categorizes the Adrenal Corticosteroid Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug
    • Aminoglutethimide
    • Levoketoconazole
    • Metyrapone
    • Osilodrostat
  • Treatment Type
    • Breast Cancer
    • Cushing's Syndrome
    • Prostate Cancer
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End-user
    • Hospitals
    • Speciality Centres
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Adrenal Corticosteroid Inhibitors Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Adrenal Corticosteroid Inhibitors Market?

3. What are the technology trends and regulatory frameworks in the Adrenal Corticosteroid Inhibitors Market?

4. What is the market share of the leading vendors in the Adrenal Corticosteroid Inhibitors Market?

5. Which modes and strategic moves are suitable for entering the Adrenal Corticosteroid Inhibitors Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing need for adrenal corticosteroid inhibitors to treat endocrine diseases
      • 5.1.1.2. Rising government approvals for adrenal corticosteroid inhibitors-based drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Limited awareness and high cost associated with adrenal corticosteroid inhibitors
    • 5.1.3. Opportunities
      • 5.1.3.1. Significant investments in research and development of adrenal corticosteroid inhibitors
      • 5.1.3.2. Growing presence of refined medical facilities and advances in pharmaceutical sector
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns regarding side impacts of adrenal corticosteroid inhibitors-based drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug: Burgeoning utilization of osilodrostat drug owing to its long-term treatment option for diseases
    • 5.2.2. Treatment Type: Increasing use of adrenal corticosteroid inhibitors for treating cushing's syndrome
    • 5.2.3. Distribution Channel: Evolving online distribution channel for adrenal corticosteroid inhibitors
    • 5.2.4. End-user: Significant adoption of adrenal corticosteroid inhibitors in specialty centers
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Adrenal Corticosteroid Inhibitors Market, by Drug

  • 6.1. Introduction
  • 6.2. Aminoglutethimide
  • 6.3. Levoketoconazole
  • 6.4. Metyrapone
  • 6.5. Osilodrostat

7. Adrenal Corticosteroid Inhibitors Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Cushing's Syndrome
  • 7.4. Prostate Cancer

8. Adrenal Corticosteroid Inhibitors Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Adrenal Corticosteroid Inhibitors Market, by End-user

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Speciality Centres

10. Americas Adrenal Corticosteroid Inhibitors Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Adrenal Corticosteroid Inhibitors Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Adrenal Corticosteroid Inhibitors Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
    • 13.3.2. U.S. FDA Approves AKEEGA (Niraparib and Abiraterone Acetate), the Dual Action Tablet for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
    • 13.3.3. Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. ADRENAL CORTICOSTEROID INHIBITORS MARKET RESEARCH PROCESS
  • FIGURE 2. ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ADRENAL CORTICOSTEROID INHIBITORS MARKET DYNAMICS
  • FIGURE 7. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. ADRENAL CORTICOSTEROID INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. ADRENAL CORTICOSTEROID INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ADRENAL CORTICOSTEROID INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY AMINOGLUTETHIMIDE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY AMINOGLUTETHIMIDE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY LEVOKETOCONAZOLE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY LEVOKETOCONAZOLE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY METYRAPONE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY METYRAPONE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY OSILODROSTAT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY OSILODROSTAT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY CUSHING'S SYNDROME, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY CUSHING'S SYNDROME, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY SPECIALITY CENTRES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY SPECIALITY CENTRES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 49. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 50. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 57. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 58. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 65. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 66. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 73. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 74. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 81. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 82. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 102. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 109. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 110. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 117. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 118. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 125. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 126. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 133. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 134. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 141. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 142. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 150. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 157. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 158. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 173. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 174. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 181. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 182. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 189. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 190. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 207. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 208. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 215. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 216. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 223. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 224. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 231. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 232. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 239. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 240. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 247. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 248. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 255. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 256. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 264. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 271. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 272. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 273. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 279. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 280. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 281. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 287. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 288. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 289. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 295. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 296. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 297. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 298. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 303. RUSSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 304. RUSSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 305. RUSSIA ADRENAL CORT